Copyright Reports & Markets. All rights reserved.

Oncology Small Molecule Drugs-Global Market Status and Trend Report 2013-2023

Request for Sample of this report
Buy now

Table of Contents

    Chapter 1 Overview of Oncology Small Molecule Drugs

    • 1.1 Definition of Oncology Small Molecule Drugs in This Report
    • 1.2 Commercial Types of Oncology Small Molecule Drugs
      • 1.2.1 Chemotherapy Drugs
      • 1.2.2 Immunomodulating Drugs
      • 1.2.3 Targeted Therapy Drugs
      • 1.2.4 Hormonal Therapy
      • 1.2.5 Other
    • 1.3 Downstream Application of Oncology Small Molecule Drugs
      • 1.3.1 Blood Cancer
      • 1.3.2 Breast Cancer
      • 1.3.3 Gastrointestinal Cancer
      • 1.3.4 Prostate Cancer
      • 1.3.5 Lung Cancer
      • 1.3.6 Other
    • 1.4 Development History of Oncology Small Molecule Drugs
    • 1.5 Market Status and Trend of Oncology Small Molecule Drugs 2013-2023
      • 1.5.1 Global Oncology Small Molecule Drugs Market Status and Trend 2013-2023
      • 1.5.2 Regional Oncology Small Molecule Drugs Market Status and Trend 2013-2023

    Chapter 2 Global Market Status and Forecast by Regions

    • 2.1 Market Development of Oncology Small Molecule Drugs 2013-2017
    • 2.2 Production Market of Oncology Small Molecule Drugs by Regions
      • 2.2.1 Production Volume of Oncology Small Molecule Drugs by Regions
      • 2.2.2 Production Value of Oncology Small Molecule Drugs by Regions
    • 2.3 Demand Market of Oncology Small Molecule Drugs by Regions
    • 2.4 Production and Demand Status of Oncology Small Molecule Drugs by Regions
      • 2.4.1 Production and Demand Status of Oncology Small Molecule Drugs by Regions 2013-2017
      • 2.4.2 Import and Export Status of Oncology Small Molecule Drugs by Regions 2013-2017

    Chapter 3 Global Market Status and Forecast by Types

    • 3.1 Production Volume of Oncology Small Molecule Drugs by Types
    • 3.2 Production Value of Oncology Small Molecule Drugs by Types
    • 3.3 Market Forecast of Oncology Small Molecule Drugs by Types

    Chapter 4 Global Market Status and Forecast by Downstream Industry

    • 4.1 Demand Volume of Oncology Small Molecule Drugs by Downstream Industry
    • 4.2 Market Forecast of Oncology Small Molecule Drugs by Downstream Industry

    Chapter 5 Market Driving Factor Analysis of Oncology Small Molecule Drugs

    • 5.1 Global Economy Situation and Trend Overview
    • 5.2 Oncology Small Molecule Drugs Downstream Industry Situation and Trend Overview

    Chapter 6 Oncology Small Molecule Drugs Market Competition Status by Major Manufacturers

    • 6.1 Production Volume of Oncology Small Molecule Drugs by Major Manufacturers
    • 6.2 Production Value of Oncology Small Molecule Drugs by Major Manufacturers
    • 6.3 Basic Information of Oncology Small Molecule Drugs by Major Manufacturers
      • 6.3.1 Headquarters Location and Established Time of Oncology Small Molecule Drugs Major Manufacturer
      • 6.3.2 Employees and Revenue Level of Oncology Small Molecule Drugs Major Manufacturer
    • 6.4 Market Competition News and Trend
      • 6.4.1 Merger, Consolidation or Acquisition News
      • 6.4.2 Investment or Disinvestment News
      • 6.4.3 New Product Development and Launch

    Chapter 7 Oncology Small Molecule Drugs Major Manufacturers Introduction and Market Data

    • 7.1 Johnson & Johnson
      • 7.1.1 Company profile
      • 7.1.2 Representative Oncology Small Molecule Drugs Product
      • 7.1.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
    • 7.2 AbbVie
      • 7.2.1 Company profile
      • 7.2.2 Representative Oncology Small Molecule Drugs Product
      • 7.2.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of AbbVie
    • 7.3 Celgene
      • 7.3.1 Company profile
      • 7.3.2 Representative Oncology Small Molecule Drugs Product
      • 7.3.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Celgene
    • 7.4 Novartis
      • 7.4.1 Company profile
      • 7.4.2 Representative Oncology Small Molecule Drugs Product
      • 7.4.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Novartis
    • 7.5 Roche
      • 7.5.1 Company profile
      • 7.5.2 Representative Oncology Small Molecule Drugs Product
      • 7.5.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Roche
    • 7.6 Pfizer
      • 7.6.1 Company profile
      • 7.6.2 Representative Oncology Small Molecule Drugs Product
      • 7.6.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Pfizer
    • 7.7 Takeda
      • 7.7.1 Company profile
      • 7.7.2 Representative Oncology Small Molecule Drugs Product
      • 7.7.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Takeda
    • 7.8 Amgen
      • 7.8.1 Company profile
      • 7.8.2 Representative Oncology Small Molecule Drugs Product
      • 7.8.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Amgen
    • 7.9 Bristol-Myers Squibb
      • 7.9.1 Company profile
      • 7.9.2 Representative Oncology Small Molecule Drugs Product
      • 7.9.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
    • 7.10 Sanofi
      • 7.10.1 Company profile
      • 7.10.2 Representative Oncology Small Molecule Drugs Product
      • 7.10.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Sanofi
    • 7.11 Merck
      • 7.11.1 Company profile
      • 7.11.2 Representative Oncology Small Molecule Drugs Product
      • 7.11.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Merck
    • 7.12 Teva
      • 7.12.1 Company profile
      • 7.12.2 Representative Oncology Small Molecule Drugs Product
      • 7.12.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Teva
    • 7.13 Eli Lilly
      • 7.13.1 Company profile
      • 7.13.2 Representative Oncology Small Molecule Drugs Product
      • 7.13.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
    • 7.14 Ipsen
      • 7.14.1 Company profile
      • 7.14.2 Representative Oncology Small Molecule Drugs Product
      • 7.14.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Ipsen
    • 7.15 Biogen Idec
      • 7.15.1 Company profile
      • 7.15.2 Representative Oncology Small Molecule Drugs Product
      • 7.15.3 Oncology Small Molecule Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
    • 7.16 Astellas
    • 7.17 Bayer
    • 7.18 Otsuka
    • 7.19 Eisai
    • 7.20 AstraZeneca
    • 7.21 Gilead Sciences
    • 7.22 Exelixis

    Chapter 8 Upstream and Downstream Market Analysis of Oncology Small Molecule Drugs

    • 8.1 Industry Chain of Oncology Small Molecule Drugs
    • 8.2 Upstream Market and Representative Companies Analysis
    • 8.3 Downstream Market and Representative Companies Analysis

    Chapter 9 Cost and Gross Margin Analysis of Oncology Small Molecule Drugs

    • 9.1 Cost Structure Analysis of Oncology Small Molecule Drugs
    • 9.2 Raw Materials Cost Analysis of Oncology Small Molecule Drugs
    • 9.3 Labor Cost Analysis of Oncology Small Molecule Drugs
    • 9.4 Manufacturing Expenses Analysis of Oncology Small Molecule Drugs

    Chapter 10 Marketing Status Analysis of Oncology Small Molecule Drugs

    • 10.1 Marketing Channel
      • 10.1.1 Direct Marketing
      • 10.1.2 Indirect Marketing
      • 10.1.3 Marketing Channel Development Trend
    • 10.2 Market Positioning
      • 10.2.1 Pricing Strategy
      • 10.2.2 Brand Strategy
      • 10.2.3 Target Client
    • 10.3 Distributors/Traders List

    Chapter 11 Report Conclusion

      Chapter 12 Research Methodology and Reference

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources

      Report Summary

      Oncology Small Molecule Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oncology Small Molecule Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

      Worldwide and Regional Market Size of Oncology Small Molecule Drugs 2013-2017, and development forecast 2018-2023
      Main manufacturers/suppliers of Oncology Small Molecule Drugs worldwide, with company and product introduction, position in the Oncology Small Molecule Drugs market
      Market status and development trend of Oncology Small Molecule Drugs by types and applications
      Cost and profit status of Oncology Small Molecule Drugs, and marketing status
      Market growth drivers and challenges

      The report segments the global Oncology Small Molecule Drugs market as:

      Global Oncology Small Molecule Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
      North America
      Europe
      China
      Japan
      Rest APAC
      Latin America

      Global Oncology Small Molecule Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
      Chemotherapy Drugs
      Immunomodulating Drugs
      Targeted Therapy Drugs
      Hormonal Therapy
      Other

      Global Oncology Small Molecule Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
      Blood Cancer
      Breast Cancer
      Gastrointestinal Cancer
      Prostate Cancer
      Lung Cancer
      Other

      Global Oncology Small Molecule Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Oncology Small Molecule Drugs Sales Volume, Revenue, Price and Gross Margin):
      Johnson & Johnson
      AbbVie
      Celgene
      Novartis
      Roche
      Pfizer
      Takeda
      Amgen
      Bristol-Myers Squibb
      Sanofi
      Merck
      Teva
      Eli Lilly
      Ipsen
      Biogen Idec
      Astellas
      Bayer
      Otsuka
      Eisai
      AstraZeneca
      Gilead Sciences
      Exelixis

      In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
      Buy now